Your browser doesn't support javascript.
loading
Antifungal drugs: New insights in research & development.
Nicola, André Moraes; Albuquerque, Patrícia; Paes, Hugo Costa; Fernandes, Larissa; Costa, Fabricio F; Kioshima, Erika Seki; Abadio, Ana Karina Rodrigues; Bocca, Anamélia Lorenzetti; Felipe, Maria Sueli.
Afiliación
  • Nicola AM; Division of Pathology, University of Brasília Medical School, Brazil.
  • Albuquerque P; Faculty of Ceilândia, University of Brasília, Brazil; Graduate Programme in Microbial Biology, University of Brasília, Brazil.
  • Paes HC; Division of Clinical Medicine, University of Brasília Medical School, Brazil.
  • Fernandes L; Faculty of Ceilândia, University of Brasília, Brazil; Graduate Programme in Microbial Biology, University of Brasília, Brazil.
  • Costa FF; Graduate Programme in Genomic Science and Biotechnology, Catholic University of Brasília, Brazil; MATTER, Chicago, IL, USA; Cancer Biology and Epigenomics Program, Ann & Robert Lurie Children's Hospital of Chicago Research Center, Northwestern University's Feinberg School of Medicine, Chicago, I
  • Kioshima ES; Department of Clinical Analysis and Biomedicine, State University of Maringá, Paraná, Brazil.
  • Abadio AKR; School for Applied Social and Agricultural Sciences, State University of Mato Grosso, Nova Mutum Campus, Mato Grosso, Brazil.
  • Bocca AL; Department of Cell Biology, Institute of Biological Sciences, University of Brasília, Brazil. Electronic address: albocca@unb.br.
  • Felipe MS; Graduate Programme in Genomic Science and Biotechnology, Catholic University of Brasília, Brazil; Department of Cell Biology, Institute of Biological Sciences, University of Brasília, Brazil. Electronic address: msueli@ucb.br.
Pharmacol Ther ; 195: 21-38, 2019 03.
Article en En | MEDLINE | ID: mdl-30347212
ABSTRACT
The need for better antifungal therapy is commonly accepted in view of the high mortality rates associated with systemic infections, the low number of available antifungal classes, their associated toxicity and the increasing number of infections caused by strains with natural or acquired resistance. The urgency to expand the range of therapeutic options for the treatment of fungal infections has led researchers in recent decades to seek alternative antifungal targets when compared to the conventional ones currently used. Although new potential targets are reported, translating the discoveries from bench to bedside is a long process and most of these drugs fail to reach the patients. In this review, we discuss the development of antifungal drugs focusing on the approach of drug repurposing and the search for novel drugs for classical targets, the most recently described gene targets for drug development, the possibilities of immunotherapy using antibodies, cytokines, therapeutic vaccines and antimicrobial peptides.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Micosis / Antifúngicos Límite: Animals / Humans Idioma: En Revista: Pharmacol Ther Año: 2019 Tipo del documento: Article País de afiliación: Brasil

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Micosis / Antifúngicos Límite: Animals / Humans Idioma: En Revista: Pharmacol Ther Año: 2019 Tipo del documento: Article País de afiliación: Brasil